Upadacitinib NEW
Price | $57 | $55 | $52 |
Package | 1box | 5box | 10box |
Min. Order: | 1box |
Supply Ability: | 5000 box |
Update Time: | 2024-11-27 |
Product Details
Product Name: Upadacitinib | CAS No.: 1310726-60-3 |
Min. Order: 1box | Purity: 99% |
Supply Ability: 5000 box | Release date: 2024/11/27 |
Upatinib sustained-release tablet is a selective JAK inhibitor developed by AbbVie and approved by the National Drug Administration in February 2022 for refractory, moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older who do not respond well to or are not suitable for other systemic therapies, such as hormonal or biologic agents. The launch of Upatinib sustained-release tablets provides more options for the treatment of atopic dermatitis patients. Approved by the State Drug Administration in March 2022 for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have poor response or intolerance to one or more TNF inhibitors and adult patients with active psoriatic arthritis (PsA) who have poor response or intolerance to one or more DMARDs. Upatinib sustained-release tablets became the first targeted therapy approved in China to treat PsA, opening a new era of targeted therapy for PsA in China. On February 20, 2023, Upatinib sustained release tablets were approved by the State Food and Drug Administration for the treatment of adult patients with moderate to severe active ulcerative colitis who have poor response to one or more TNF inhibitors or are intolerant or conjunctive, becoming the four approved indications in China after atopic dermatitis, psoriatic arthritis and rheumatoid arthritis. It is also the first approved indication of the drug in the field of gastroenterology in China.
It works by blocking the activity of Janus kinase in the JAK-STAT signaling pathway, an intracellular pathway that plays a major role in the release of pro-inflammatory cytokines that stimulate inflammation in rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis
Hebei Weimiao Network Technology Co., Ltd. is a professional production and sales of chemical, cosmetic raw materials, plant extracts, cosmetics, pharmaceutical intermediates, metal materials manufacturers.
Founded in Hebei Province, the company has developed into a professional enterprise integrating
production, sales and technology development. At present, our products havebeen exported to Europe, the Middle East, Southeast Asia, the United States, Latin America, South America, Australia and other countries and regions. We will be your proud partner in China.
We will be a Chinese partner that make you proud , and we make efforts to provide you with professional and timely service.Look forward to establishing a good faith and friendly relationship with you.
Company Profile Introduction
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/25KG |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2024-10-22 | |
$0.00/10g |
VIP1Y
|
Cangzhou Kangrui Pharma Tech Co. Ltd.,
|
2024-10-16 | |
$0.00/10Gram |
VIP1Y
|
Hangzhou Hyper Chemicals Limited
|
2024-09-06 | |
$1.00/1kg |
VIP1Y
|
S&Y Biochem Co.,Ltd
|
2024-08-08 | |
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-07-24 | |
$1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-11 | |
$30.00/1kg |
VIP1Y
|
hebei hongtan Biotechnology Co., Ltd
|
2024-05-17 | |
$0.00/25kg |
VIP1Y
|
PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD
|
2024-05-15 | |
$0.10/1kg |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2024-02-16 | |
$0.00/1Kg/Bag |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2023-11-03 |
- Since: 2015-04-17
- Address: Building A, Zhonghua Street, Qiaoxi District, Shijiazhuang City, Hebei Province